CSF-HM401B-100μg / 询价
CSF-HM401B-500μg / 询价
CSF-HM401B-500μgx2 / 询价
Biotinylated Human M-CSF/CSF-1 Protein
Recombinant Biotinylated Human M-CSF/CSF-1 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Glu33-Asn190.[Accession | P09603-1]
The protein has a predicted MW of 21.3 kDa. Due to glycosylation, the protein migrates to 27-37 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human M-CSF on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human M-CSF is greater than 95% as determined by SEC-HPLC.
Immobilized Human M-CSF R, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human M-CSF, His Tag with the EC50 of 19.4ng/ml determined by ELISA.
CSF-1, also known as M-CSF , is a four alpha -helical-bundle cytokine that is the primary regulator of macrophage survival, proliferation and differentiation. CSF-1 is also essential for the survival and proliferation of osteoclast progenitors.CSF-1 is cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes.
CSF1; CSF-1; MCSF; M-CSF; MGC31930; Lanimostim
(1)Cannarile M A , Weisser M , Jacob W , et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy[J]. Journal for ImmunoTherapy of Cancer, 2017, 5(1):53.
